CA2239331C - Comprimes pharmaceutiques a base de cefuroxime axetil - Google Patents

Comprimes pharmaceutiques a base de cefuroxime axetil Download PDF

Info

Publication number: CA2239331C
Authority: CA; Canada
Prior art keywords: cefuroxime axetil; carbonate; tablet; bicarbonate; tablets
Prior art date: 1998-05-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2239331

Other languages

English (en)

Inventor

Bernard Charles Sherman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-29

Filing date

1998-05-29

Publication date

1999-11-30

1998-05-29 Application filed by Individual filed Critical Individual

1998-05-29 Priority to CA 2239331 priority Critical patent/CA2239331C/fr

1999-05-18 Priority to AU38074/99A priority patent/AU3807499A/en

1999-05-18 Priority to PCT/CA1999/000446 priority patent/WO1999062559A1/fr

1999-11-30 Application granted granted Critical

1999-11-30 Publication of CA2239331C publication Critical patent/CA2239331C/fr

2018-05-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 title claims abstract description 22
229960002620 cefuroxime axetil Drugs 0.000 title claims abstract description 22
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 11
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims abstract description 10
239000007884 disintegrant Substances 0.000 claims description 10
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
239000002244 precipitate Substances 0.000 claims description 6
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
229960000913 crospovidone Drugs 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
229960001681 croscarmellose sodium Drugs 0.000 claims description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
239000001095 magnesium carbonate Substances 0.000 claims description 2
229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
229940079832 sodium starch glycolate Drugs 0.000 claims description 2
239000008109 sodium starch glycolate Substances 0.000 claims description 2
229920003109 sodium starch glycolate Polymers 0.000 claims description 2
239000003826 tablet Substances 0.000 description 21
238000010521 absorption reaction Methods 0.000 description 8
239000000203 mixture Substances 0.000 description 7
239000012530 fluid Substances 0.000 description 6
230000002496 gastric effect Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000037406 food intake Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
-1 for example Polymers 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2239331 1998-05-29 1998-05-29 Comprimes pharmaceutiques a base de cefuroxime axetil Expired - Fee Related CA2239331C (fr)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CA 2239331 CA2239331C (fr)	1998-05-29	1998-05-29	Comprimes pharmaceutiques a base de cefuroxime axetil
AU38074/99A AU3807499A (en)	1998-05-29	1999-05-18	Pharmaceutical tablets comprising cefuroxime axetil
PCT/CA1999/000446 WO1999062559A1 (fr)	1998-05-29	1999-05-18	Comprimes pharmaceutiques comprenant du cefuroxime axetil

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2239331 CA2239331C (fr)	1998-05-29	1998-05-29	Comprimes pharmaceutiques a base de cefuroxime axetil

Publications (1)

Publication Number	Publication Date
CA2239331C true CA2239331C (fr)	1999-11-30

Family

ID=4162505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2239331 Expired - Fee Related CA2239331C (fr)	1998-05-29	1998-05-29	Comprimes pharmaceutiques a base de cefuroxime axetil

Country Status (3)

Country	Link
AU (1)	AU3807499A (fr)
CA (1)	CA2239331C (fr)
WO (1)	WO1999062559A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT413647B (de) *	1998-11-26	2006-04-15	Sandoz Ag	Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
ATE369842T1 (de) *	2002-03-04	2007-09-15	Orbus Pharma Inc	Zusammensetzungen mit schneller freisetzung enthaltend cefuroxime axetil
WO2005002540A2 (fr) *	2003-07-01	2005-01-13	Ranbaxy Laboratories Limited	Compositions de cefuroxime axetil sous forme de suspensions pharmaceutiques pulverulentes seches
KR100552567B1 (ko) *	2003-08-23	2006-02-15	한국유나이티드제약 주식회사	수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
GB0400971D0 (en) *	2004-01-16	2004-02-18	Sandoz Ag	Pharmaceutical compositions
CN104230957B (zh) *	2013-06-09	2017-02-08	广东立国制药有限公司	头孢呋辛酸的制备方法及该过程中去除dcc内酯的方法
CN106109433A (zh) *	2016-08-10	2016-11-16	瑞阳制药有限公司	头孢呋辛酯薄膜衣片及其制备方法
CN114191375B (zh) *	2021-12-20	2022-07-26	广东金城金素制药有限公司	一种注射用头孢呋辛钠及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU44680B (en) *	1982-07-30	1990-12-31	Glaxo Lab Ltd	Process for obtaining very pure amorphous form of cephuroxim axetile
ES8502863A1 (es) *	1982-09-10	1985-02-01	Glaxo Group Ltd	Un procedimiento para la produccion de un recipiente hermeticamente cerrado que contiene al menos un antibiotico de beta-lactama.
GB8524001D0 (en) *	1985-09-30	1985-11-06	Glaxo Group Ltd	Pharmaceutical composition
CA2209868C (fr) *	1997-08-15	2001-08-14	Bernard Charles Sherman	Compositions pharmaceutiques a base de cefuroxime axetil

1998
- 1998-05-29 CA CA 2239331 patent/CA2239331C/fr not_active Expired - Fee Related
1999
- 1999-05-18 AU AU38074/99A patent/AU3807499A/en not_active Abandoned
- 1999-05-18 WO PCT/CA1999/000446 patent/WO1999062559A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO1999062559A1 (fr)	1999-12-09
AU3807499A (en)	1999-12-20

Legal Events

Date	Code	Title	Description
1999-02-10	EEER	Examination request
2007-05-29	MKLA	Lapsed

Publication	Publication Date	Title
US5064656A (en)	1991-11-12	Uncoated pharmaceutical reaction tablet
AU639137B2 (en)	1993-07-15	Superior tasting pharmaceutical composition having porous particles and the process of preparing such pharmaceutical composition
EP0250023B1 (fr)	1991-08-14	Forme de dosage de la nitrofurantoine
CA2182004C (fr)	2000-10-31	Comprimes enrobes de paracetamol et de domperidone
IE58951B1 (en)	1993-12-01	Solid pharmaceutical preparations for oral administration containing 9-deoxo-11-deoxy-9, 11-(IMINO(2-(2-methoxyethoxy)ethylidene)-oxy)-(9s)-erythromycin and processes for the preparation thereof
CA2000763C (fr)	2000-11-14	Produit dispersant
GB2105590A (en)	1983-03-30	Flotable controlled release preparations
EP2968174B1 (fr)	2019-10-16	Comprimés de composition pharmaceutique orale à double utilisation de sels de sulfate et leurs procédés d'utilisation
CA2239331C (fr)	1999-11-30	Comprimes pharmaceutiques a base de cefuroxime axetil
US3865935A (en)	1975-02-11	Tableting of erythromycin base
EP1429748B1 (fr)	2005-07-20	Compositions solides comprenant du ramipril
CA2408796C (fr)	2009-12-15	Procede servant a stabiliser une preparation
EP1684728B1 (fr)	2009-09-16	Forme non effervescente de naproxene de sodium comprenant du bicarbonate de soude
EP0121901B1 (fr)	1988-03-16	Pastilles à libération contrôlée indépendante du PH
US6485744B1 (en)	2002-11-26	Stabilized cefuroxime axetil
CA1108992A (fr)	1981-09-15	Composition pharmaceutique contenant du 1,3-bis(2- carboxychromone-5-yloxy)2-hydroxypropane
CA2071262C (fr)	1998-02-03	Formes posologiques stabilisees de solides de compositions de salicylatede carboxymethylcellulose metallique de choline
CA2049817A1 (fr)	1992-02-28	Formulations de gemfibrozil
RU2200558C1 (ru)	2003-03-20	Лекарственное средство, содержащее финастерид
AU2002325125A1 (en)	2003-04-14	Solid compositions comprising ramipril
WO2003063867A1 (fr)	2003-08-07	Comprimes stables exempts de saccharides, comprenant un sel de quinapril ou de moexipril
MXPA96004298A (en)	1998-09-18	Solid dose forms containing bism